• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form E filed

    12/23/20 12:15:27 AM ET
    $NVUS
    Major Pharmaceuticals
    Health Care
    Get the next $NVUS alert in real time by email
    EDGAR Filing Documents for 9999999995-20-003635
    Home | Latest Filings | Previous Page
    SEC Seal
    SEC Banner
    Search the Next-Generation EDGAR System
    Filing Detail
    • SEC Home »
    • Search the Next-Generation EDGAR System »
    • Company Search »
    • Current Page
    Form EFFECT - Notice of Effectiveness:
    SEC Accession No. 9999999995-20-003635
    Accepted
    2020-12-23 00:15:27
    Documents
    1
    Effectiveness Date
    2020-12-22
    Registration Form
    S-3

    Document Format Files

    Seq Description Document Type Size
    1 primary_doc.html EFFECT  
    1 primary_doc.xml EFFECT 594
      Complete submission text file 9999999995-20-003635.txt   1816
    Mailing Address 19900 MACARTHUR BLVD. SUITE 550 IRVINE CA 92612
    Business Address 19900 MACARTHUR BLVD. SUITE 550 IRVINE CA 92612 949-238-8090
    Novus Therapeutics, Inc. (Filer) CIK: 0001404281 (see all company filings)

    IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
    Type: EFFECT | Act: 33 | File No.: 333-251305 | Film No.: 201409662
    SIC: 2834 Pharmaceutical Preparations
    Office of Life Sciences

    Get the next $NVUS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NVUS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NVUS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Novus Therapeutics Announces Name Change to Eledon Pharmaceuticals; Provides Corporate Update and Outlook

    Eledon to commence trading on the Nasdaq exchange under the ticker “ELDN” effective tomorrow, January 5, 2021 Eledon is well financed to complete up to four Phase 2 clinical trials of lead candidate AT-1501, a potential best in class anti-CD40L monoclonal antibody IRVINE, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for persons living with an autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis (ALS), today provided a corporate update and offered its outlook for 2021 and beyond. 2020 a

    1/4/21 8:00:00 AM ET
    $NVUS
    Major Pharmaceuticals
    Health Care

    Novus Therapeutics Announces Results of Special Meeting of Stockholders

    IRVINE, Calif., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for patients undergoing organ or cellular transplantation, as well as those living with immunological diseases, today announced results from a special meeting of stockholders that was held on Friday, December 19, 2020. During the meeting, Novus’ stockholders approved a proposal for the issuance of common shares upon conversion of Series X¹ non-voting convertible preferred stock issued at the time of the company’s acquisition of Anelixis Therapeutics, Inc., and concurrent private placement (PI

    12/22/20 8:00:00 AM ET
    $NVUS
    Major Pharmaceuticals
    Health Care

    Novus Therapeutics Appoints June Lee, M.D., to Board of Directors

    IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for patients undergoing organ or cellular transplantation, as well as those living with immunological diseases, today announced the appointment of June Lee, M.D., to the company’s Board of Directors. “We are delighted to welcome June to our board of directors as Novus continues on this next phase of its evolution,” said David-Alexandre C. Gros, M.D., Chief Executive Officer of Novus Therapeutics, Inc. “Over a twenty plus year career as a clinician, academic, executive, and respected leader in the biote

    12/9/20 8:30:00 AM ET
    $NVUS
    Major Pharmaceuticals
    Health Care

    $NVUS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by Sean Paul Little

    3 - Eledon Pharmaceuticals, Inc. (0001404281) (Issuer)

    3/19/21 7:00:19 AM ET
    $NVUS
    Major Pharmaceuticals
    Health Care

    $NVUS
    SEC Filings

    View All

    SEC Form 8-K filed by Novus Therapeutics, Inc.

    8-K - Eledon Pharmaceuticals, Inc. (0001404281) (Filer)

    3/15/21 2:00:32 PM ET
    $NVUS
    Major Pharmaceuticals
    Health Care

    SEC Form 8-K filed

    8-K - Eledon Pharmaceuticals, Inc. (0001404281) (Filer)

    1/7/21 8:00:54 AM ET
    $NVUS
    Major Pharmaceuticals
    Health Care

    SEC Form SC 13D/A filed

    SC 13D/A - Eledon Pharmaceuticals, Inc. (0001404281) (Subject)

    1/5/21 4:38:07 PM ET
    $NVUS
    Major Pharmaceuticals
    Health Care

    $NVUS
    Leadership Updates

    Live Leadership Updates

    View All

    Novus Therapeutics Appoints June Lee, M.D., to Board of Directors

    IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for patients undergoing organ or cellular transplantation, as well as those living with immunological diseases, today announced the appointment of June Lee, M.D., to the company’s Board of Directors. “We are delighted to welcome June to our board of directors as Novus continues on this next phase of its evolution,” said David-Alexandre C. Gros, M.D., Chief Executive Officer of Novus Therapeutics, Inc. “Over a twenty plus year career as a clinician, academic, executive, and respected leader in the biote

    12/9/20 8:30:00 AM ET
    $NVUS
    Major Pharmaceuticals
    Health Care

    $NVUS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed

    SC 13G - Eledon Pharmaceuticals, Inc. (0001404281) (Subject)

    2/16/21 4:35:45 PM ET
    $NVUS
    Major Pharmaceuticals
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - Eledon Pharmaceuticals, Inc. (0001404281) (Subject)

    2/16/21 4:17:16 PM ET
    $NVUS
    Major Pharmaceuticals
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - Eledon Pharmaceuticals, Inc. (0001404281) (Subject)

    2/16/21 3:14:46 PM ET
    $NVUS
    Major Pharmaceuticals
    Health Care

    $NVUS
    Financials

    Live finance-specific insights

    View All

    Novus Therapeutics Announces Name Change to Eledon Pharmaceuticals; Provides Corporate Update and Outlook

    Eledon to commence trading on the Nasdaq exchange under the ticker “ELDN” effective tomorrow, January 5, 2021 Eledon is well financed to complete up to four Phase 2 clinical trials of lead candidate AT-1501, a potential best in class anti-CD40L monoclonal antibody IRVINE, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for persons living with an autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis (ALS), today provided a corporate update and offered its outlook for 2021 and beyond. 2020 a

    1/4/21 8:00:00 AM ET
    $NVUS
    Major Pharmaceuticals
    Health Care